RxSight, Inc. Stock 12‑Month Price Target Cut to $7.19, Implies 57% Upside

What happened

RxSight, Inc.’s average 12-month stock price target from eight analyst estimates fell from $7.57 to $7.19, with forecasts ranging from $5.50 to $11 per share. Based on the Nov. 3 closing price, the updated target implies approximately 57% potential upside. The consensus rating remains Hold.

Confirmed

Global impact / market context

The lower average target signals that analysts’ valuation expectations have weakened, even though the revised figure still sits above the Nov. 3 closing price. If investors use these targets to guide decisions, changing expectations could influence demand for the stock and the company’s ability to raise capital through share sales.

Analyst inference

The ratings are mixed rather than uniformly positive: among 10 covering analysts, one recommends Buy, seven recommend Hold and two recommend Sell. This spread suggests uncertainty about the shares’ prospects; the implied upside is an estimate, not a promised return or a forecast of actual trading.

Analyst inference

What to watch

1. Watch for changes in the average target and its forecast range; further cuts could reinforce weaker analyst expectations, while upward revisions would indicate improved valuation views. Analyst inference
2. Track the balance of Buy, Hold and Sell ratings among covering analysts, since a shift could change investor positioning and demand for RxSight shares. Analyst inference
3. Compare future targets with the share price used to calculate implied upside, because price movements can change the apparent gap even without target revisions. Analyst inference

Evidence

• Original source link unavailable